Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Development of rational drug combinations with investigational targeted agents.

× No keyword cloud information.

2 in total

Review 1. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.

Authors: Jeffrey A Engelman
Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531

2. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Authors: Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; Jose Baselga; Neal Rosen
Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701

2 in total

3 in total

1. When it takes two to tango, FDA suggests a new regulatory dance.

Authors: Elie Dolgin
Journal: Nat Med Date: 2011-03 Impact factor: 53.440

2. Opportunities and challenges in the development of experimental drug combinations for cancer.

Authors: Rachel W Humphrey; Laura M Brockway-Lunardi; David T Bonk; Kathleen M Dohoney; James H Doroshow; Sandra J Meech; Mark J Ratain; Suzanne L Topalian; Drew M Pardoll
Journal: J Natl Cancer Inst Date: 2011-07-15 Impact factor: 13.506

3. The Cytotoxicity of the Ajoene Analogue BisPMB in WHCO1 Oesophageal Cancer Cells Is Mediated by CHOP/GADD153.

Authors: Vuyolwethu Siyo; Georgia Schäfer; Roger Hunter; Andriy Grafov; Iryna Grafova; Martin Nieger; Arieh A Katz; M Iqbal Parker; Catherine H Kaschula
Journal: Molecules Date: 2017-05-28 Impact factor: 4.411

3 in total